약물 관련 골괴사 (MRONJ)의 최신 견해: 종설

키워드

참고문헌 (72)

1. Rosen LS, "Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial", Cancer, 100, pp.2613~2621 (2004)
2. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update", J Oral Maxillofac Surg, 67, pp.2~12 (2009)
3. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)
4. 김경민, "Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons", 대한골대사학회지, 22(4), pp.151~165 (2015), 대한골대사학회
5. 김진우, "Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons", 대한골대사학회지, 28(4), pp.279~296 (2021), 대한골대사학회
6. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons’position paper on medication-related osteonecrosis of the jaws-2022update", J Oral Maxillofac Surg, 80, pp.920~943 (2022)
7. Etminan M, "Use of oral bisphosphonates and the risk of aseptic osteonecrosis : a nested case-control study", J Rheumatol, 35, pp.691~695 (2008)
8. Tennis P, "Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis", Pharmacoepidemiol Drug Saf, 21, pp.810~817 (2012)
9. Bone HG, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", J Clin Endocrinol Metab, 96, pp.972~980 (2011)
10. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)
11. Khan AA, "Diagnosis and management of osteonecrosis of the jaw : a systematic review and international consensus", J Bone Miner Res, 30, pp.3~23 (2015)
12. Giovannacci I, "Medication-related osteonecrosis of the jaw around dental implants: implant surgery-triggered or implant presence-triggered osteonecrosis?", J Craniofac Surg, 27, pp.697~701 (2016)
13. Malden N, "An epidemiological study of alendronate-reof Scotland with attention given to case definition and prevalence", J Bone Miner Metab, 30, pp.171~182 (2012)
14. Ulmner M, "Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate", J Oral Maxillofac Surg, 72, pp.76~82 (2014)
15. Powell D, "Incidence of serious side effects with intravenous bisphosphonate : a clinical audit", QJM, 105, pp.965~971 (2012)
16. Lo JC, "Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure", J Oral Maxillofac Surg, 68, pp.243~253 (2010)
17. Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
18. Russell RG, "Mechanisms of action of bisphosphonates : similarities and differences and their potential influence on clinical efficacy", Osteoporos Int, 19, pp.733~759 (2008)
19. Baron R, "Denosumab and bisphosphonates : different mechanisms of action and effects", Bone, 48, pp.677~692 (2011)
20. Marx RE, "Oral bisphosphonate-induced osteonecrosis:risk factors, prediction of risk using serum CTX testing, prevention, and treatment", J Oral Maxillofac Surg, 65, pp.2397~2410 (2007)
21. Lesclous P, "Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?", Bone, 45, pp.843~852 (2009)
22. Hansen T, "Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis", Virchows Arch, 451, pp.1009~1017 (2007)
23. Sedghizadeh PP, "Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy", J Oral Maxillofac Surg, 66, pp.767~775 (2008)
24. Wood J, "Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid", J Pharmacol Exp Ther, 302, pp.1055~1061 (2002)
25. Landesberg R, "Potential pathophysiological mechanisms in osteonecrosis of the jaw", Ann N Y Acad Sci, 1218, pp.62~79 (2011)
26. Hoefert S, "Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw : presentation of three cases", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 110, pp.463~469 (2010)
27. Wynn RL, "Bevacizumab(Avastin) : an anti-angiogenic drug associated with osteonecrosis of the jaw", Gen Dent, 59, pp.410~413 (2011)
28. Sonis ST, "Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients", Oral Oncol, 45, pp.164~172 (2009)
29. Marx RE, "Bisphosphonate-induced exposed bone (osteonecrosis", osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment, 2005, pp.63, 1567~1575
30. Thumbigere-Math V, "A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates", Am J Clin Oncol, 35, pp.386~392 (2012)
31. Marini F, "Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw", Front Biosci(Elite Ed), 3, pp.364~370 (2011)
32. Yang G, "SIRT1", HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw : an exome-wide association analysis, 2018, pp.33, 91~98
33. Lee KH, "Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis : a case control study", J Transl Med, 17, pp.381~ (2019)
34. Yang G, "SIRT1 gene SNP rs932658 is associated with medication-related osteonecrosis of the jaw", J Bone Miner Res, 36, pp.347~356 (2021)
35. Marx RE, "A decade of bisphosphonate bone complications : what it has taught us about bone physiology", Int J Oral Maxillofac Implants, 29, pp.e247~58 (2014)
36. Watts NB, "Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years", J Clin Endocrinol Metab, 104, pp.2443~2452 (2019)
37. Boquete-Castro A, "Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials", Clin Oral Implants Res, 27, pp.367~375 (2016)
38. Ng TL, "Long-term impact of bone-modifying agents for the treatment of bone metastases : a systematic review", Support Care Cancer, 29, pp.925~943 (2021)
39. Inada A, "Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database", Ther Clin Risk Manag, 15, pp.59~64 (2019)
40. Kim SH, "Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates : a nationwide cohort-study", Bone, 143, pp.115650~ (2021)
41. 이정근, "Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report", 대한구강악안면외과학회지, 39(1), pp.9~13 (2013), 대한구강악안면외과학회
42. Duarte NT, "Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review", Int J Oral Maxillofac Surg, 49, pp.183~191 (2020)
43. Brown JJ, "Bisphosphonate-associated osteonecrosis of the jaw : does it occur in children?", Clin Endocrinol(Oxf), 68, pp.863~867 (2008)
44. Saad F, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases", Ann Oncol, 23, pp.1341~1347 (2012)
45. Tsao C, "Oral health risk factors for bisphosphonate-associated jaw osteonecrosis", J Oral Maxillofac Surg, 71, pp.1360~1366 (2013)
46. Kyrgidis A, "Bisphosphonate-related osteonecrosis of the jaws : a case-control study of risk factors in breast cancer patients", J Clin Oncol, 26, pp.4634~4638 (2008)
47. Vahtsevanos K, "Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw", J Clin Oncol, 27, pp.5356~5362 (2009)
48. Japanese Allied Committee on Osteonecrosis of the J, "Antiresorptive agent-related osteonecrosis of the jaw : position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw", J Bone Miner Metab, 35, pp.6~19 (2017)
49. Fliefel R, "Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw(BRONJ)with characterization of patients : a systematic review", Int J Oral Maxillofac Surg, 44, pp.568~585 (2015)
50. Yamazaki T, "Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates : a cohort study", Int J Oral Maxillofac Surg, 41, pp.1397~1403 (2012)
51. Mucke T, "Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid-A prospective study over 6 years", J Craniomaxillofac Surg, 44, pp.1689~1693 (2016)
52. Sim Ie W, "Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer", J Clin Endocrinol Metab, 100, pp.3887~3893 (2015)
53. Damm DD, "Bisphosphonate-related osteonecrosis of the jaws : a potential alternative to drug holidays", Gen Dent, 61, pp.33~38 (2013)
54. Cummings SR, "Vertebral fractures after discontinuation of denosumab : a post hoc analysis of the randomized placebo-controlled freedom trial and its extension", J Bone Miner Res, 33, pp.190~198 (2018)
55. Awad ME, "Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy : systematic review and meta-analysis", J Am Dent Assoc, 150, pp.664~675 (2019)[DOI]
56. Kwon YD, "Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws", J Oral Maxillofac Surg, 67, pp.2644~2648 (2009)
57. Park JH, "Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw : a prospective clinical study", Osteoporos Int, 33, pp.367~377 (2022)
58. Chalem M, "Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw(MONJ) : recommendations of a multidisciplinary group of experts", Arch Osteoporos, 15, pp.101~ (2020)
59. Jacobsen C, "Osteopathology induced by bisphosphonates and dental implants : clinical observations", Clin Oral Investig, 17, pp.167~175 (2013)
60. Schiodt M, "Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws : a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system", Oral Surg Oral Med Oral Pathol Oral Radiol, 117, pp.204~213 (2014)
61. Hadaya D, "Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care", J Oral Maxillofac Surg, 76, pp.2332~2339 (2018)
62. Carlson ER, "The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws", J Oral Maxillofac Surg, 67, pp.85~95 (2009)
63. Freiberger JJ, "What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw : a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics", J Oral Maxillofac Surg, 70, pp.1573~1583 (2012)
64. Bashutski JD, "Teriparatide and osseous regeneration in the oral cavity", N Engl J Med, 363, pp.2396~2405 (2010)
65. Carlson ER, "Management of antiresorptive osteonecrosis of the jaws with primary surgical resection", J Oral Maxillofac Surg, 72, pp.655~657 (2014)
66. Nisi M, "Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws : a series of 120 patients", Br J Oral Maxillofac Surg, 54, pp.930~935 (2016)
67. Hinson AM, "Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw : a pooled case report analysis", J Oral Maxillofac Surg, 73, pp.53~62 (2015)
68. Blick SK, "Teriparatide : a review of its use in osteoporosis", Drugs, 68, pp.2709~2737 (2008)
69. Dhillon RS, "PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis", J Bone Miner Res, 28, pp.586~597 (2013)
70. McClung MR, "Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass", Arch Intern Med, 165, pp.1762~1768 (2005)
71. Sim IW, "Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial", J Clin Oncol, 38, pp.2971~2980 (2020)
72. Cheung A, "Teriparatide therapy for alendronate-associated osteonecrosis of the jaw", N Engl J Med, 363, pp.2473~2474 (2010)

관련 논문AI추천